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Objectives: PVI is the preferred initial revasculariza-
tion strategy at many centers in patients with critical limb
ischemia (CLI). Using a multicenter, regional database we
sought to determine if previous failed ipsilateral, infraingui-
nal PVI (iiPVI) portends worsened outcomes after subse-
quent lower extremity bypass (LEB) in patients with CLI.
Methods: This is a retrospective cohort analysis of the
Vascular Study Group of New England (VS GNE) database of
infrainguinal lower extremity bypass for CLI (2003-2008).
Study endpoints were major amputation, graft occlusion and
mortality rates at one year, and in-hospital major adverse events
(MAE). Outcomes were determined using Kaplan-Meier analy-
sis and Cox Proportional-Hazard multivariate regression.
Results: Of 1, 153 patients who underwent LEB for
CLI, 71 (6.2%) had a prior failed iiPVI. One year mortality
and in-hospital MAE did not differ between the groups.
Patients undergoing prior iiPVI had significantly higher
rates of graft occlusion and amputation at one year (Table).
Multivariate predictors of 1-yr LEB occlusion were prior
iiPVI (HR 1.8; CI 1.1-2.9), arm vein conduit (HR 1.8; CI
1.1-2.6), and tibial outflow (HR 2.0; CI 1.4-2.9). Multi-
variate predictors of 1-yr major amputation were iiPVI (HR
2.0; CI 1.0-3.7), dialysis (HR 4.2; 2.6-6.6), prior ipsilateral
bypass (HR 1.7; CI 1.1-2.8), tibial outflow (HR 1.9; CI
1.3-2.9), and tissue loss (HR 1.7; CI 1.1-2.7).
Conclusions: Failed iiPVI is an important predictor of

















Occlusion (1-yr) 16% 31% 0.01 16% 24% 0.08
Amputation (1-yr) 14% 23% 0.08 14% 21% 0.03
Death (1-yr) 10% 13% 0.97 10% 10% 0.95
MAE (in-hospital) 29% 32% 0.5 29% 29% 0.91
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SS15.
Sustained 5 Years Performance Analysis of Sequential Com-
pression Biomechanical Device (SCBD) in Critical Limb
Ischaemia (CLI) Patients with Un-reconstructable Periph-
eral Vascular Disease (PVD) vs Primary Amputation in a
Tertiary Referral Vascular Centre With Quality of Time
Without the Symptoms or Toxicity of the Disease
(QTWiST)
Sherif Sultan, Nader Hamada, Wael Tawfick, Anne Fahy,
Niamh Hynes. Vascular & Endovascular Surgery, Western
Vascular Institute, Galway, IrelandObjectives: Our aim was assess the clinical efficacy and
economic viability of a SCBD programme for CLI. Primary
endpoints were sustained clinical improvement and ampu-
tation free survival. Secondary endpoints were Q-TWiST
and cost per QALY.
Methods: From 2004 to 2009, we assessed 4538 pa-
tients with PVD. Of which 707 had CLI and 518 had
intervention, while 189 were not candidates for any inter-
vention. Only 170 patients had joined the SCBD pro-
gramme for three months at three hours bi-daily. We
matched controlled 75 primary amputations. All patients
were Rutherford category 4 or more. The median fol-
low-up was 13 months with average of 18.3 months.
Results: Sustained clinical improvement was reported in
68% of patients. Sustained hemodynamic improvement were
notedwith;Mean toe pressure increased from39.9mmHg to
55.42mmHgwith mean difference in Toe Pressure of 15.49
mmHg p 0.0001; andMean Popliteal flow increased from
35.44cm/sec to 55.91cm/sec with Mean Difference in Pop-
liteal Flow of 20.47cm/sec p 0.0001. Thirty-day mortality
was 0.6%.Mean Amputation-free survival rate was 18months
with limb salvage rate at 5years of 94%. Freedom fromMACE
at 5 Years was 62.5%. All cause survival was 68.4%% at 5 years.
Estimatedmedian Inpatient/Total cost of managing a prima-
ry-amputation patient is €29, 815 compared to €3985 for
SCBD.We treated170patientswith artassist at a cost of €681,
965. However, primary amputation for 75 patients had cost
€2, 236, 125 with poor QALY/QTWiST.
Conclusions: SCBD Improves Quality of Life at a
Community Level. This study provides larger scale evi-
dence that SCBD therapy is a cost-effective and clinically
efficacious solution as it has Superior Limb Salvage, Ame-
liorated Amputation Free Survival, Reduced Length of
Hospital Stay and Provided Rapid Relief of Rest Pain
without any Intervention in Patients with Limited Life
Expectancy.
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A Comparison of Endovascular Revascularization and
Bypass in Regards to Healing Rates of Ischemic
Wounds
Richard F. Neville, John Steinberg, Joe Babrowicz, James
Laredo, David Deaton, Christopher E. Attinger. Surgery,
Georgetown University Hospital, Washington, DC
Objectives: Compare wound healing after endovascu-
lar therapy (EV) or lower extremity bypass (LEB) to inves-
tigate equivalence based on tissue results and wound char-
acteristics.
Methods: A retrospective review analyzed 290 patients
undergoing revascularization for an ischemic wound from
January 2004 to December 2008. Inclusion required com-
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Analysis of degree and rate of healing was performed based
on initial wound size.
Results:The study included142LEBand148EVpatients
with similar age (EV 70, LEB 71), diabetes mellitus (EV 58%,
LEB 41%), and chronic renal failure (EV 24%, LEB 21%). EV
procedures (balloon angioplasty n 20, stent deployment n
82, atherectomy n  30, and cryoplasty n  10) treated SFA
(30%), popliteal (19%), and tibial (51%) lesions with 2.8 lesions
treated per patient. LEB included 98 vein grafts and 44 using
PTFE with a distal vein patch. Target arteries included BK pop-
liteal (n 14), anterior tibial (n 46), posterior tibial (n 41),
and peroneal (n 41). Therewas no difference in average initial
wound size (EV14.1mm,LEB14.6mm)with complete healing
in 76% after LEB and 41% after EV (p 0.013). This difference
was significant in larger wounds (Group C) with complete heal-
ing in 70%LEB and 27%EV (p 0.02). A shortermedian time
to healing was noted after bypass; LEB 98 days, EV 132 days
(p 0.048). There were 40 amputations; EV 30 (20% total, 8%
major), and LEB 10 (7% total, 2.8%major).
Conclusions: This comparison of wound healing after
bypass or endovascular revascularization demonstrates
more complete healing and a faster rate of healing after
open bypass for larger wounds ( 2 cm). Initial wound size
should be a consideration in choosing the method of
revascularization for ischemic wounds.
Healing based on initial wound size
Group LEB EV
A (0-5 mm) 81.1% 94 days 53.8% 105 days
B (5.1 – 20 mm) 76.2% 102 days 41.7% 128 days
C ( 20 mm) * 70.2% 115 days 27.1% 164 days
*p  0.01
Author Disclosures: C. E. Attinger: Nothing to disclose;
J. Babrowicz: Nothing to disclose; D. Deaton: Nothing
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Video Presentation
Popliteal to Dorsalis Pedis Translocated Vein Graft
Frank W. LoGerfo1, Frank B. Pomposelli1, Allen Hamdan1,
Bernadette Aulivola2. 1Beth Israel Deaconess Medical Center,
Boston,MA; 2Loyola UniversityMedical center, Chicago, IL
Background: Autogenous vein bypass grafts to the dor-
salis pedis artery are an essential surgical skill in the care of
patients with foot ulcers associated with Diabetes Mellitus.
Technical Description: This is a video showing the key
steps in the performance of a popliteal to dorsalis pedis translo-
cated vein graft demonstrating angioscopically verified valve lysis.
Author Disclosures: B. Aulivola: Nothing to disclose; A.
Hamdan: Nothing to disclose; F. W. LoGerfo: Nothing
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Vacuum-Assisted Closure (VAC) Therapy for the Treat-
ment of Deep (Szilagyi Grade III-Infection) in the Groin
Ramesh Tripathi1, Kiriakos Ktenidis2. 1Vascular & Endo-
vascular Surgery, Indraprastha Apollo Hospital, New
Delhi, Hungary; 2Aristotle University, Thessaloniki, Greece
Objectives: To evaluate the benefit of vacuum-assisted
closure (VAC) therapy for the treatment of deep alloplastic
graft infections (Szilagyi Grade III-Infection) in the groin.
Methods: From 2000 to 2009, 72 deep inguinal infec-
tions involving native as well as synthetic graft or patch
material. There were 29 early graft infections ( 30 days
after implantation) and 43 late infections. 55 cases involved
non-native grafts/patches (26 PTFE grafts, 24 Dacron
grafts, 5 Vascuguard Bovine Pericardial patches). All pa-
tients were treated with multiple wound debridements,
graft salvage, sartorius myoplasty, IV antibiotics and VAC
dressings till thru-surface healing was achieved. Exclusion
criteria were an alloplastic graft infection with proximal
expansion above the inguinal ligament, blood culture pos-
itive septicaemia or septic anastomotic herald or overt
bleeding.
Results: At 9 months, overall, graft/patch salvage was
achieved in 70/72 (97.2%) patients. In the non-native
group, vein or synthetic graft preservation without revision
was achieved in 48/55 (82.27%) patients. The mean dura-
tion of VAC treatment was 16  7.7 days, postoperative
mean hospital stay was 25.3 8.5 days. In 23 (31.9%) cases
a secondary closure of the wound could be achieved. In 49
cases wound healing was achieved by meshed split skin
grafting. Mean wound healing time for all wounds was
24.3 12.5 days. Mean postoperative follow-up was 4.3
3.5 years with no procedure-related mortality. Specific
complications during VAC-therapy were wound fluid re-
tention in 2 cases and an increased need for analgesics in 12
patients.
Conclusions: Even in the presence of synthetic vascu-
lar graft material, negative pressure therapy can greatly
simplify challenging wound-healing problems. Our long-
term experience demonstrates the safety and effectiveness
of VAC-therapy for the treatment of deep graft infections.
Author Disclosures: K. Ktenidis: Nothing to disclose; R.
Tripathi: Nothing to disclose.
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Low Rehospitalization Rate for Vascular Surgery Pa-
tients at a Single University Hospital
Benjamin M. Jackson1, Lynne Doctor2, Derek Nathan3,
Grace J. Wang1, Edward Y. Woo1, Ronald M. Fairman1.
1Hospital of the Univeristy of Pennsylvania - Division of
Vascular Surgery, Philadelphia, PA; 2University of Pennsyl-
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Objectives: Reducing rehospitalization rates has been
proposed to improve care, reduce costs, and as a pay-for-
performance criterion. Recent review of Medicare claims
